Plus Therapeutics
$1.38
22
-$0-0.22% Wednesday 20:00
Statistik
Harga Tertinggi Hari
1.38
Harga Terendah Hari
1.32
52M Tertinggi
2.78
52M Terendah
0.97
Volum
9,679
Volum Purata
61,726
Kapasiti Pasaran
8.43M
Nisbah P/E
-
Pendapatan Dividen
-
Dividen
-
Pendapatan
23OctDijangka
EPS yang dijangka
-0.5625
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti PSTV. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
Gritstone Bio
GRTS
Kapasiti Pasaran56.31M
Ayala Pharmaceuticals
ADXS
Kapasiti Pasaran851,880
Mustang Bio
MBIO
Kapasiti Pasaran10.47M
CRISPR Therapeutics
CRSP
Kapasiti Pasaran4.06B
Bluebird bio
BLUE
Kapasiti Pasaran108.22M
Fate Therapeutics
FATE
Kapasiti Pasaran417.93M
Allogene Therapeutics
ALLO
Kapasiti Pasaran549.96M
Penilaian Penganalisis
14$Sasaran Harga Purata
Anggaran tertinggi adalah $20.
Dari 2 penilaian dalam tempoh 6 bulan terakhir. Ini bukan cadangan pelaburan.
Beli
100%
Pegang
0%
Jual
0%
Mengenai
Health Technology
Biotechnology
Manufacturing
Surgical and Medical Instrument Manufacturing
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Show more...
CEO
Marc Hedrick
Pekerja
20
Negara
US
ISIN
US72941H4002